Application and prospect of universal CAR-NK cell therapy for systemic lupus erythematosus
10.16781/j.CN31-2187/R.20240262
- VernacularTitle:通用型CAR-NK细胞治疗系统性红斑狼疮的应用与展望
- Author:
Yiyi YU
1
;
Jiaqi HU
;
Zhengyi JIN
;
Ruina KONG
;
Jie GAO
Author Information
1. 海军军医大学(第二军医大学)第一附属医院风湿免疫科,上海 200433
- Keywords:
systemic lupus erythematosus;
chimeric antigen receptor;
natural killer cells;
universal type
- From:
Academic Journal of Naval Medical University
2024;45(10):1199-1204
- CountryChina
- Language:Chinese
-
Abstract:
Systemic lupus erythematosus(SLE)is characterized by a large number of anti-autoantibodies produced by abnormally activated B cells,which form immune complexes with autoantigens to induce systemic inflammation,leading to the involvement of multiple systems and organs.Existing treatment strategies targeting B cells(such as belimumab,telitacicept,and rituximab)had limited efficacy.Recently,CD 19 targeting chimeric antigen receptor(CAR)-T cell has shown excellent efficacy in the treatment of SLE.However,autologous CAR-T cell therapy has potential risks such as cytokine release syndrome(CRS),T cell tumors,and infections,and it is expensive.CAR-natural killer(NK)cell therapy,on the other hand,is an off-the-shelf cellular therapy with high safety,no neurotoxicity or tumorigenic risk,and with low treatment costs.Currently,CAR-NK cell has achieved remarkable research results in treating hematological malignancies,and preliminary clinical studies of CAR-NK cell therapy for SLE have showed good efficacy,excellent safety,and predictable durability.This article focuses on the characteristics of the new generation of universal CAR-NK cell and the latest clinical research results for the treatment of relapsed and refractory SLE,offering insights into its promising future in the treatment of SLE and B-cell-related autoimmune diseases.
